Guidance
← Earnings Calls
01
02
03
04 05 06
Tone
A1 A2 A3 A4
INCY
FY2025 Q4
Improving
Incyte Corporation earnings call
Buzzberg read
Core business ex-Jakafi expected to grow over 30% in 2026
Incyte reported strong Q4 and FY2025 results, beating guidance with 20% product revenue growth. Management guided 2026 to revenue of $4.77-4.94B, up 10-13%, and projected core (ex-Jakafi) growth of ~30%, driven by a maturing pipeline and multiple upcoming launches. The call focused on execution across oncology, hematology, and immunology, notably highlighting the pivotal data for Monjuvi in DLBCL and the potential for Povacitinib in HS, while managing expectations for Jakafi XR conversion. FY2025 total revenues grew 21% to $5.14B, with product sales up 20% to $4.35B, exceeding guidance.
Buzzberg read Core business ex-Jakafi expected to grow over 30% in 2026 Incyte reported strong Q4 and FY2025 results, beating guidance with 20% product revenue growth. Management guided 2026 to revenue of $4.77-4.94B, up 10-13%, and projected core (ex-Jakafi) growth of ~30%, driven by a maturing pipeline and multiple upcoming launches. The call focused on execution across oncology, hematology, and immunology, notably highlighting the pivotal data for Monjuvi in DLBCL and the potential for Povacitinib in HS, while managing expectations for Jakafi XR conversion. FY2025 total revenues grew 21% to $5.14B, with product sales up 20% to $4.35B, exceeding guidance. Read full analysisCollapse analysis
Incyte reported strong Q4 and FY2025 results, beating guidance with 20% product revenue growth. Management guided 2026 to revenue of $4.77-4.94B, up 10-13%, and projected core (ex-Jakafi) growth of ~30%, driven by a maturing pipeline and multiple upcoming launches. The call focused on execution across oncology, hematology, and immunology, notably highlighting the pivotal data for Monjuvi in DLBCL and the potential for Povacitinib in HS, while managing expectations for Jakafi XR conversion. FY2025 total revenues grew 21% to $5.14B, with product sales up 20% to $4.35B, exceeding guidance.
- Core business (ex-Jakafi) is guided to grow ~30% in 2026, driven by strong uptake of Monjuvi, Nictimbo, and Opsalura.
- Four key product launches are anticipated in late 2026/early 2027: Jakafi XR, Monjuvi in frontline DLBCL, Povacitinib for HS, and Opsalura for HS.
- Povacitinib NDA accepted, targeting large pre-biologic HS population as first oral treatment.
HEM_ONC Revenue$0.583BReported
JAKAFI Revenue$3.093BReported
OPSALURA Revenue$0.678BReported
PRODUCT_SALES Revenue$4.35BReported
6 grounded callouts
What matters now
The highest-signal changes from the call.
Pipeline
Jakafi XR approval and launch expected mid-2026
Regulatory
Povacitinib NDA submitted for HS, filing acceptance this quarter
Show 3 more callouts
Clinical Data
FrontMIND trial met primary endpoint PFS in first-line DLBCL
Pipeline
Opluura PN development paused after FDA feedback
Guidance
Management expects four product approvals in late 2026 and early 2027
Reported period
Actuals
| Metric | Reported | Change |
|---|---|---|
| HEM_ONC Revenue | $0.583B | Reported |
| JAKAFI Revenue | $3.093B | Reported |
| OPSALURA Revenue | $0.678B | Reported |
| PRODUCT_SALES Revenue | $4.35B | Reported |
| Revenue | $1.5068B | Reported |
| EPS | $1.80 | Reported |
Forward-looking
Forward guidance
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| Operating marginRD_SGA | FY2026 | $3.495B–$3.675B | $3.585B | Maintained |
| Revenue | FY2026 | $4.77B–$4.94B | $4.855B | Maintained |
| RevenueJAKAFI | FY2026 | $3.22B–$3.27B | $3.245B | Maintained |
| RevenueOPSALURA | FY2026 | $0.75B–$0.79B | $0.77B | Maintained |
| RevenueHEM_ONC | FY2026 | $0.8B–$0.88B | $0.84B | Maintained |
| RevenueCORE_EX_JACKIFY | FY2026 | $1.57B–$1.69B | $1.63B | Maintained |
AI, capex & demand read
Management read
Confident
Management expressed strong confidence in the pipeline and growth trajectory, emphasizing multiple catalysts and a clear path to replace Jakafi.
External signals
Supply-chain alpha · 4returns since call
Incyte is executing a deliberate transition: expecting 4 product launches in late 2026/early 2027 (Jakafi XR, Monjuvi frontline DLBCL, Povacitinib HS, Opsalura), with the core business (ex-Jakafi) guided to ~30% growth in 2026.
Evidence
“Sales for our core business, X-Jackify, will range between $1.57 and $1.69 billion, representing roughly a 30% growth rate at the midpoint in 2026.”
Formulary negotiations for future Jakafi XR are in progress, with management expecting enough coverage to enable a 10-30% conversion rate from the IR version, contributing minimal revenue in 2026 but significant potential by 2029.
Evidence
“With an extended release formulation like Jackify, you're probably not going to reach into that top tier of formulary coverage. But we should get enough formulary coverage to enable a conversion rate of 10% to 30%.”
Incyte’s KRAS G12D (734) and TGF-betaR2xPD-1 (A9O) programs target 'wide open white spaces' in pancreatic and MSS colorectal cancer, aiming to be first or early to market with potential for significant market share.
Evidence
“These are, these are the largest wide open white spaces in cancer. We could be first or early in pancreatic and we could be first and only in colorectal.”
Povacitinib’s opportunity is to capture the 75% of HS patients not on advanced systemics, focusing on the pre-biologic population currently cycling through antibiotics/steroids.
Evidence
“There's 150,000 people using products that are not approved for HS, antibiotics, and steroids. Our ability to drive sales of povocitinib is to get to that group...”
Methodology & coverage
Management-only analysis. All 0 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.